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Abstract
Objective: To evaluate the performance of the updated version of European System for Cardiac Operative Risk Evaluation
(EuroSCORE II) for prediction of in-hospital mortality after mitral valve replacement.
Patients and methods: Medical records of 580 Egyptian patients underwent mitral valve replacement in Nasser institute, Suez
Canal University, and Minia University hospitals were evaluated in six-year period. Data on demographics, comorbidities, risk
factors, operative outcome and postoperative complications were collected with in-hospital mortality as primary end-point. Sta-
tistical analysis assessed discriminative power and calibration of EuroSCORE II.
Results: The study population had younger age, more prevalence of female gender and higher body mass index (BMI) than
EuroSCORE II population. The observed in-hospital mortality rate was 2.6% and average of the predicted mortality by Euro-
SCORE II was 1.60%. EuroSCORE II had low discriminative power (area under the curve 0.52, 95% CI: 0.38e0.66), and poor
calibration as determined by HosmereLemeshow (HL) test (P-value¼ 0.02). On multivariate analysis, other factors not involved in
EuroSCORE II were significant predictors for in-hospital mortality including redo-operation, previous valvuloplasty, hypercho-
lesterolemia and chronic liver disease.
Conclusion: Differences in clinical profile and presence of other local risk factors may explain the reduced discriminative and
predictive power of EuroSCORE II in Egyptian patients underwent mitral valve replacement. Other larger prospective studies in
this concern are recommended.
Copyright © 2016, The Egyptian Society of Cardio-thoracic Surgery. Publishing services by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
During preoperative evaluation of patients undergoing cardiac surgery, risk stratification is helpful to determine
outcome associated with such operations and to identify the treatable conditions that may help to reduce the risk of
morbidity and mortality [1].* Corresponding author.
E-mail address: doctor2001eg@yahoo.com (M.A. Amr).
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model that was established during 1995e1999 to present a risk model in adult European patients undergoing cardiac
surgery [2].
Changing epidemiology of cardiac surgery and improvement of surgical techniques affected the calibration of
EuroSCORE. To overcome this problem, EuroSCORE II is available since October 2011, in order to maintain and
optimize its role in contemporary cardiac surgical practice [3].
Nowadays, EuroSCORE II is well accepted and routinely used in clinical practice in many countries [4]. However,
limitations in the inter-observer reliability of a risk-predicting model raise the need for external validation of Euro-
SCORE II in larger populations and in other geographic regions [5,6].
The aim of this study was to assess the role of EuroSCORE II risk model in predicting in-hospital mortality of
Egyptian patients undergoing mitral valve replacement.
2. Patients and methods
2.1. Study population
This retrospective study evaluated the medical records of 580 adult patients who underwent mitral valve
replacement in departments of cardiac surgery at the Nasser Institute, Suez Canal University Hospital and Minia
University Hospital in Egypt, between January 2010 and December 2015.
The collected data included preoperative risk factors of EuroSCORE II: age, female gender, creatinine clearance,
extracardiac arteriopathy, poor mobility due to musculoskeletal or neurological dysfunction, previous cardiac surgery,
chronic pulmonary disease, active endocarditis, critical state, diabetes on insulin, New York Heart Association (NYHA)
functional classification, Canadian Cardiovascular Society (CCS) grade IVof angina, left ventricular ejection fraction
(LVEF), recentmyocardial infarction (MI), systolic pulmonary arterypressure (sPAP), urgencyof operation,weight of the
intervention and surgeryon thoracic aorta [3].Medical recordswith lacking of datawere excluded fromanalysis (17 out of
597 records). EuroSCORE II was calculated using online interactive calculator (http://www.euroscore.org/calc.html).
The primary end point was in-hospital all-cause mortality that was defined as death occurring at any time after
surgery during in-hospital period. Additional data on other preoperative risk factors or comorbidities, operative data,
major operative and postoperative complications was collected if available.
2.2. Statistical analysis
Statistical analysis was performed with the SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). The quantitative
data were presented as mean and standard deviation or median (interquartile range) and compared using t-student test
while qualitative data were expressed by number and percentage and compared using Chi-square test.
The discriminative power of EuroSCORE II model was estimated by the area under the receiver operating char-
acteristic (ROC) curve which was calculated as an index to discriminate between lived and died patients after cardiac
surgery. The results were presented with 95% confidence interval (CI) and P-value < 0.05 was considered significant.
The discriminative power of the model was considered good if area under the curve (AUC) was >0.70.
To estimate EuroSCORE II model calibration, the HosmereLemeshow goodness of fit test and calibration plots
were used to compare observed to predicted values by decile of predicted probability. Awell-calibrated model for the
study population was considered when HosmereLemeshow p-value > 0.05.
To identify, other independent predictors of mortality, multivariate logistic regression was performed with
calculation of odds ratio (OR), 95% confidence interval (CI) and significance level (P-value) for risk factors of
mortality that had a statistical significance on univariate analysis.
3. Results
3.1. Patients' characteristics
The study included 580 patients underwent isolated mitral valve replacement (MVR). The age ranged from 18 to 67
years with mean of 41.3 ± 11.2 years and 48.2% of the included patients were female. The preoperative and
Table 1
Preoperative and intraoperative characteristics of the study cohort.
Variables Patients underwent MVR (n ¼ 580)
Age (years); mean ± SD (range) 40 ± 13 (18e67)
Female gender; n (%) 280 (48.2%)
EuroSCORE II; median (range) 1.60 (0.50e27.2)
Renal function:
- Normal 546 (94.13%)
- Moderate impairment 24 (4.13%)
- Severe impairment 10 (1.72%)
Extracardiac arteriopathy 9 (1.55%)
Previous cardiac surgery 14 (2.41%)
Chronic pulmonary disease 10 (1.72%)
Active endocarditis 15 (2.6%)
Critical preoperative state 15 (2.6%)
Diabetes on insulin therapy 10 (1.72%)
NYHA functional class:
- NYHA I 5 (0.86%)
- NYHA II 235 (40.51%)
- NYHA III 285 (49.13%)
- NYHA IV 35 (6.03%)
CCS class 4 angina 10 (1.72%)
LV function:
- Fair (30e49%) 18 (3.10%)
- Good (>50%) 562 (96.89%)
Pulmonary hypertension 29 (5%)
Other than isolated CABG 580 (100%)
Redo-operation 18 (3.10%)
Diabetes mellitus 15 (2.6%)
Hypertension 9 (1.55%)
Previous valvuloplasty 10 (1.72%)
Hypercholesterolemia 6 (1.03%)
Smoking (Ex-smoker or still-smoking) 92 (15.86%)
Chronic liver disease 19 (3.27%)
Cardioplegia method:
- Cold cardioplegia 525 (90.51%)
- Warm cardioplegia 55 (9.48%)
Coming off bypass:
- High inotropic support 1 (0.17%)
- Minimal inotropic support 399 (68.79%)
- No inotropic support 180 (31.03%)
Bypass time (min); median (range) 75 (38e255)
Cross-clamp time (min); median (range) 55 (21e213)
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(94.13%), good left ventricular (LV) function (96.89%), NYHA functional class III (49.13%), and most of them
underwent elective MVR (93.96%) for first time (96.89%). Most of operations were done using cold cardioplegia
(90.51%), with minimal need for inotropic support (68.79%).
Comparison of preoperative risk factors and demographics between Egyptian patients cohort who underwent mitral
valve replacement (MVR) and EuroSCORE II population (Table 2), revealed presence of significant differences in the
clinical profiles as Egyptian surgical population had younger age, more prevalence of female gender and higher body
mass index (BMI).3.2. Immediate postoperative outcome
Regarding the immediate postoperative results (Table 3), median length of ICU stay was 24 h (range: 18e340 h),
and median total hospital stay was 9 days (range: 5e44 days), with 18.10% of patients had total hospital stay for
more than 15 days. Low incidences of postoperative complications were reported, including neurological
Table 2
Comparison of preoperative risk factors and demographics between Egyptian patients cohort underwent mitral valve replacement (MVR) and
EuroSCORE II population.
Variables Egyptian population underwent




Age (years); mean ± SD (range) 41.3 ± 11.2 (18e67) 64.6 ± 12.5 (18e95) <0.001a
Female gender; n (%) 280 (48.2%) 6919 (30.9%) <0.001a
Body mass index (kg/m2) 29.08 ± 8.9 27.4 ± 4.8 <0.001a
Diabetes on insulin therapy 10 (1.7%) 1705 (7.6%) <0.001a
Pulmonary disease 10 (1.7%) 2384 (10.7%) <0.001a
Neurological dysfunction with poor mobility 0 (0%) 713 (3.2%) <0.001a
Creatinine clearance (ml/min) 87.75 ± 15.14 83.6 ± 50.9 0.04a
Active endocarditis 15 (2.6%) 497 (2.2%) 0.55
Critical preoperative state 15 (2.6%) 924 (4.1%) 0.06
Emergency operation 20 (3.44%) 4135 (18.5%) <0.001a




Variables Patients underwent MVR (n ¼ 580)
Stay on ICU (hours); median (range) 24 (18e340)
Total hospital stay (days); median (range) 9 (5e44)
Long hospital stay > 15 days; n (%) 105 (18.10%)
Neurological complications 1 (0.17%)
Prolonged ventilation 5 (0.86%)
DSW infection 3 (0.51%)
Renal complications 0 (0%)
Reoperation 6 (1.03%)
Low cardiac output 4 (0.68%)
Arrhythmias 1 (0.17%)
Pulmonary complications 1 (0.17%)
Readmitted to ICU 1 (0.17%)
Mortality 15 (2.6%)
ICU: Intensive care unit, DSW: Deep sternal wound.
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in 1.03%, low cardiac output in 0.68%, arrhythmias in 0.17%, pulmonary complications in 0.17% and readmission
to ICU in 0.17%.3.3. Observed and predicted mortalities
The observed rate of in-hospital mortality was 2.6% (n ¼ 15 patients). The predicted mortality by EuroSCORE
II ranged from 0.50 to 27.2% with mean of 1.60%. The expected 1st quartile of EuroSCORE II was 0.67% in 145
patients, while 2nd was 0.80% in another 145 patients, 3rd quartile was 1.13% in 150 patients and 4th quartile
was >1.13% in 140 patients. Table 4 distributes observed in-hospital mortality in relation to expected quartilesTable 4
Observed in-hospital mortality in relation to expected quartiles of mortality estimated by EuroSCORE II.
Outcome Quartiles of EuroSCORE II
0e0.67% 0.68e0.80% 0.81e1.13% >1.13%
Alive 142 (97.9%) 139 (95.9%) 148 (98.7%) 136 (97.1%)
Died 3 (2.1%) 6 (4.1%) 2 (1.3%) 4 (2.9%)
Total 145 145 150 140
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quartile, 1.3% of 3rd quartile and 2.9% in 4th quartile, with non-significant difference (P ¼ 0.47). Fig. 1 rep-
resents a histogram of real observed mortality in relation to predicted quartiles of EuroSCORE II, indicating non-
parametric distribution of died patients as most of them were in 1st and 2nd quartiles of EuroSCORE II.
3.4. Accuracy (discriminative power)
As shown in (Fig. 2), the area under the ROC curve (AUC) for the EuroSCORE II was 0.52 (95% CI, 0.38e0.66)
with no statistical significance (P¼ 0.77), indicating that EuroSCORE II had low discriminative power to distinguish
between incidences of died and alive patients.
3.5. Calibration (predictive power)
The HosmereLemeshow (HL) goodness-of-fit test showed a significant difference between expected and observed
mortality according to EuroSCORE II model (Chi-square ¼ 16.2, P¼ 0.02), indicating poor calibration of this model
in predicting the overall in-hospital mortality (Fig. 3).
3.6. Other predictors of in-hospital mortality
On multivariate logistic regression (Table 5), other factors not involved in EuroSCORE II were significant pre-
dictors for in-hospital mortality in our study cohort which included redo-operation (Odds ratio: 57.67; 95% CI:
10.51e316.34; P ¼ 0.0001), previous valvuloplasty (Odds ratio: 50.32; 95% CI: 5.50e459.74; P ¼ 0.001), hyper-
cholesterolemia (Odds ratio: 34.64; 95% CI: 1.11e1073.91; P ¼ 0.043) and chronic liver disease (Odds ratio: 17.82;
95% CI: 2.20e143.96; P ¼ 0.007).
4. Discussion
The rheumatic etiology is the leading reason of valve surgery in Egypt while the degenerative etiology is the
leading reason of valve surgery in western countries. The rheumatic fever in Egypt has an aggressive course because of
the reluctance to give proper prophylactic courses of long acting penicillin. Accordingly more patients require surgery
in younger age compared with the western population. Other common and endemic liver diseases in Egypt likeFig. 1. Histogram of real observed mortality in relation to predicted quartiles of EuroSCORE II.
Fig. 2. The receiver operating characteristic (ROC) curve for EuroSCORE II. The area under curve (AUC) was 0.52.
Fig. 3. Calibration plot of observed and predicted mortality by EuroSCORE II.
Table 5
Results of multivariate logistic regression of other risk factors for in-hospital mortality not involved in EuroSCORE II.
Risk factors Odds ratio 95.0% CI for odds ratio P-value
Lower Upper
Redo-operation 57.67 10.51 316.34 <0.001a
Previous valvuloplasty 50.32 5.50 459.74 0.001a
Hypertension 8.28 0.43 158.09 0.160
Hypercholesterolemia 34.64 1.11 1073.91 0.04a
Smoking 3.08 0.63 14.95 0.162
Chronic liver disease 17.82 2.20 143.96 0.007a
CI: Confidence interval.
a Significant independent predictors.
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presentation makes the patients arrive to surgery in more advanced state of valve fibrosis and calcification than in
western countries and that made more patients require replacement of their valves rather than repair [7,8]. In addition,
lack of sticking to proper oral anticoagulant therapy by patients, especially those coming from far rural areas and
oases, made redo valve surgery for valve related complications a common practice in major cardiac centers in Egypt.
Risk-predicting models have an important role in perioperative care for patients undergoing cardiac surgery. Since
its development and validation in 1999, EuroSCORE has been widely used to predict in-hospital mortality in patients
undergoing cardiac surgery [9]. The updated version, EuroSCORE II, was proved in some studies to be better cali-
brated than the original model yet preserves powerful discrimination [3]. However, in respect to differences in the
clinical profile of the reference population and the testing sample, external validation studies were performed outside
the boundaries of the population EuroSCORE II was built upon, to verify its quality as a risk-predicting reference
[10,11]. Some clinical differences have emerged in external validation cohorts [6,12,13].
Scant data are available regarding external validation of EuroSCORE II in heart valve surgery, with controversy in
results. The studies performed in Chinese patients showed good discriminative power and calibration of EuroSCORE
II in single-valve surgery [14e16]. In a study on Pakistani patients by Rabbani et al. [17], EuroSCORE II was an
accurate predictor for individual operative risk in isolated valve surgery. In contrast to these findings, a study from
Brazil by Lisboa et al. [18], concluded poor calibration of EuroSCORE II to predict mortality in patients undergoing
valve surgery.
In the present study, we evaluated discriminative power and calibration of EuroSCORE II in Egyptian patients
undergoing isolated mitral valve surgery. The discrimination performance is important to determine how the model
distinguishes between alive and died patients during in-hospital period. Calibration is also important to determine the
agreement between the real observed and the predicted mortality.
EuroSCORE II has poor calibration and low discriminative power in our surgical population, with significant
differences in preoperative demographics and risk factors when compared to European population on whom Euro-
SCORE II was developed and validated. In addition, other significant predictors of in-hospital mortality which not
involved in EuroSCORE II were determined in our study including redo-operation, previous valvuloplasty, hyper-
cholesterolemia and chronic liver disease.
These findings may be explained by the differences in the clinical base of two different surgical populations. In
countries where EuroSCORE was developed and validated, more patients underwent heart valve surgery for
degenerative causes; however this profile is different from developing countries where valve surgery is more frequent
mainly for rheumatic causes [15].
We should be cautious in utilization of this risk stratification model outside the countries of origins. The differences
in demographic characteristics and comorbid conditions between Egyptian and European population should be
respected. Young age of patients at operation, obesity and prevalence of female gender reflect specific criteria of
Egyptian patients. Also, endemic chronic comorbid conditions such as chronic liver disease in Egypt must be
considered.
In conclusion, other risk factors affecting outcome after cardiac surgery should be re-evaluated to increase
the accuracy and predictive power of EuroSCORE II, particularly in populations outside the boundaries where it
was initially validated. The differences in preoperative comorbidity between Egyptian and European patients raise
the need for larger studies, to establish new specific risk stratification model or to renew the currently used scoring
system.Conflict of Interest
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